MedTrace Logo

AZD1152 in Patients With Advanced Solid Malignancies

NCT00338182 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2017-04-24

No results posted yet for this study

Summary

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.

Conditions

Interventions

DRUG

AZD1152 part A

48-hour continuous intravenous infusion

DRUG

AZD1152 part B

2-hour intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Emerging Oncology Medical Science Director, MD · AstraZeneca

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-23
Primary Completion
2008-06-06
Completion
2017-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00338182 on ClinicalTrials.gov